Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years of age~2. Able to give informed consent and willing to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures~3. Type 1 or type 2 diabetes with a hemoglobin A1c (HbA1c) ≤ 10% at Screening and on a stable antidiabetic medication regimen for at least 30 days prior to Screening (insulin therapy is acceptable)~4. Painful distal symmetrical sensorimotor polyneuropathy (as per American Society of Pain Educators guidelines ) diagnosed for at least 6 months, based on neurological history and/or examination; diagnosis includes absent or reduced deep tendon reflexes at both ankles~5. At Screening, a pain score of ≥ 40 mm on the SF-MPQ VAS~6. At Randomization, a pain score of ≥ 40 mm on the SF-MPQ VAS and an ADPS of ≥ 4 on the 11-point NRS, the latter calculated from a minimum of 4 pain ratings in daily diaries obtained during the 1-week Baseline Period (prior to randomization)~7. Creatinine clearance \> 60 mL/min (estimated using the Cockcroft-Gault equation)~8. Antidiabetic and other medications anticipated to remain stable and constant during the study period~9. Women of child bearing potential (WOCBP) must be using an adequate method of contraception as detailed in the protocol to avoid pregnancy during the study and for 4 weeks after study completion~Exclusion Criteria:~1. Diagnosis of mononeuropathy~2. Use of concomitant medications that may confound assessments of efficacy and/or safety (see Section 5.2)~3. Major psychiatric disorders~4. Have had a malignancy other than basal cell carcinoma within the past 2 years~5. At Visit 1, have a white blood cell count \< 2500/mm3, neutrophil count \< 1500/mm3, or platelet count \< 100 x 103/mm3~6. Clinically significant unstable diabetes mellitus, unstable hepatic, respiratory, or hematologic illness, unstable cardiovascular disease (including myocardial infarction in the 3 months prior to Visit 1), or symptomatic peripheral vascular disease~7. Clinically significant findings on the Screening ECG~8. History of pernicious anemia, untreated hypothyroidism, chronic hepatitis B, hepatitis B within the past 3 months, or human immunodeficiency virus infection~9. Amputations of body parts other than toes~10. Prior therapeutic failure of pregabalin or gabapentin (considered unresponsive or intolerant to treatment); therapeutic failure implies lack of efficacy following full titration to effective doses (eg, 300 mg/day for pregabalin)~11. Known hypersensitivity to pregabalin or gabapentin~12. Requirement for concomitant anticonvulsant and antidepressant therapy, with the exception of stable doses of SSRIs~13. Neurologic disorders unrelated to DPN that may confound the assessment of pain associated with DPN~14. Skin conditions that could alter sensation~15. Other sources of pain that may confound assessment or self-evaluation of the pain due to DPN~16. Abuse of prescription medications, street drugs or alcohol (including alcohol dependence) within the last 1 year~17. Current enrollment in another investigational study, participation in another investigational study with the past 30 days, or other current or recent use of any investigational drug~18. Pregnancy (as based on lab test results) or breast feeding~19. Laboratory values exceeding limits listed in Table 4.1 of the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-5565 5mg nighttime (Type: EXPERIMENTAL): DS-5565 5 mg/day (one 5 mg tablet at bedtime)
- DS-5565 10 mg at bedtime (Type: EXPERIMENTAL): DS-5565 10 mg/day (one 10 mg tablet at bedtime)
- DS-5565 15 mg at bedtime (Type: EXPERIMENTAL): DS-5565 15 mg/day (one 5 mg tablet plus one 10 mg tablet at bedtime)
- DS-5565 20 mg total per day (Type: EXPERIMENTAL): DS-5565 20 mg/day (one 10 mg tablet in the morning and one 10 mg tablet at bedtime)
- DS-5565 30 mg total per day (Type: EXPERIMENTAL): DS-5565 30 mg/day (one 5 mg tablet plus one 10 mg tablet in the morning and one 5 mg tablet plus one 10 mg tablet at bedtime)
- Pregabalin 300 mg total per day (Type: ACTIVE_COMPARATOR): Pregabalin 300 mg/day (two 150 mg capsules, in the morning and at bedtime)

Based on this trial design, predict the completion outcome and termination type (if applicable).